JANX vs UNH

Janux Therapeutics maintains significant 10x growth potential, underpinned by its innovative TRACTr platform and strategic focus on T-cell engagers for solid tumors and now autoimmune diseases. The Bristol Myers Squibb collaboration provides substantial validation and non-dilutive funding, bolstering its already strong cash position of approximately $1B. Anticipated clinical data readouts througho...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...